Table 2 Alternative TKIs investigated in patients with advanced imatinib refractory GIST

Pazopanib^a

2 (at least)

II

No

–

SD-48%

NPR-17%

1.9 mo

10.7 mo

2014

[54]

Pazopanib^a

2

II

Yes

BSC

SD Pazopanib-84%

84%

3.4 versus 2.3 (p = 0.03)

17.8 versus 12.9 mo

2016

[55]

BSC-71%

Cabozantinib^a

2

II

No

–

PR-14%

80%

6.0 mo

14.4 mo

2019

[56]

SD-66%

Sorafenib^a

2

II

No

–

PR-13%

36% at 24 wks

4.9 mo

9.7 mo

2012

[57]

SD-52%

Sorafenib^a

2

II

No

–

PR-13%

68%

5.2 mo

11.6 mo

2011

[58]

SD-55%

Nilotinib^a

2

II

No

–

PR-3%

29% at 24 wks

3.7 mo

10 mo

2011

[59]

SD-26%

Dasatinib^a

2

II

No

–

PR-32%

56%

1.8 mo

19 mo

2011

[41]

SD-24%

Ponatinib

3

II

No

–

PR-7%

37%

2.0 mo

13.5 mo

2014

[60]

Masitinib

1

II

Yes

Sunitinib

–

–

3.7 versus 1.9 mo

29.8 versus 17.4 mo

2014

[61]

Vatalanib

1

II

No

–

PR-4.4%

40%

4.5 mo (mTTP)

–

2011

[62]

SD-35.6%

Dovitinib

2

II

No

–

PR-3%

13%

3.6 mo

9.7 mo

2014

[63]

SD 10%

Avapritinib^a

2 or 3

III

Yes

Regorafenib

PR—17.1%(avapritinib) versus 7.2% (regorafenib)

4.2 mo (A) versus 5.6 mo (R)

–

2020

[34]